Boehringer outlines up to $33.6m for cancer asset from OSE Therapeutics

Retrieved on: 2024-05-23 18:24:34

Tags for this article:

Click the tags to see associated articles and topics

Boehringer outlines up to $33.6m for cancer asset from OSE Therapeutics. View article details on hiswai:

Excerpt

The gold standard of business intelligence. Find out more. Related Company Profiles. Boehringer Ingelheim International GmbH · OSE Immunotherapeutics ...

Article found on: www.clinicaltrialsarena.com

View Original Article